'De-nol' - a drug for the treatment of ulcerative defects, erosions of the stomach and duodenum

Diseases of the digestive organs include a large group of diseases of the stomach and intestines. The most common diseases are chronic gastritis and ulcerative defects. In these cases, the mechanism of regulation of the formation of gastric juice, the violation of the ratio of the acid-peptic factor and the defense forces of the organism, the destruction of the gastric mucosa with the formation of ulcerative defects and erosion are observed.

The causes of erosive gastritis and stomach ulcers are many. In recent decades, there have been a lot of data on the involvement in the occurrence of ulcers and the maintenance of an inflammatory process in the gastric membrane, Gram-negative microorganism - Helicobacter pylori. The specific mobility of this bacterium allows it to move in a viscous medium, such as gastric juice. With gastritis and ulcers, this bacterium is found in most cases. It has the ability to fix and function on epithelial cells, reducing the production of mucus and changing its quality.

The normal state of the mucosa is maintained by an equilibrium of aggressive and protective factors. Gastric mucus is a protective component that protects the mucous membrane from the aggression of hydrochloric acid. Also, protective factors include normal blood supply to the stomach and its good ability to regenerate. Aggressive factors include increased production of hydrochloric acid and pepsin, poor gastric motility, traumatization of the stomach and duodenal ulcers of Helicobacter pylori.

The drug treatment of gastritis and gastric ulcers is appointed by the gastroenterologist and represents a complex of drugs whose action is directed to the irradiation of Helicobacter pylori, suppression of hyperproduction of hydrochloric acid, protection of the mucosa and the regeneration of erosions and ulcerative defects.

One of the main drugs used in a complex of antiulcer therapy is "De-nol". In its composition, the drug "De-nol" contains bismuth oxide. De-nol and its antiulcer activity are associated with an inhibitory (bactericidal) effect on Helicobacter pylori. De-nol is able to envelop mucous, forming a protective shell of bismuth compounds on ulcerous and erosive defects. The drug has an anti-inflammatory effect, increases the activity of protective factors. This is achieved by increasing the formation of prostaglandins, gastric mucus and bicarbonate. In areas of ulcerative or erosive defect, De-nol causes an increase in tissue regeneration. The drug suppresses the activity of pepsin.

Bismuth does not go beyond the digestive tract, a small amount of it is absorbed into the blood. The drug is excreted through the intestine.
The drug "De-nol", is used in the treatment of ulcerative lesions of the stomach and duodenum, during an exacerbation, with chronic gastritis and gastroduodenitis, gastroenteritis and functional digestive disorders.
The drug is prescribed for the treatment of these diseases in adults and children, starting with four years. The calculation of the dosage of the drug in childhood is made per kilogram of the child's body weight. The reception takes place half an hour before meals, washed down with a small amount of water. The duration of treatment is determined by the nature of the disease and is usually one to two months.

The medicine is usually well tolerated. Undesirable reactions are rarely observed and can be expressed in dyspepsia and stool disorders, with long-term use, the development of encephalopathy is possible.

The drug should not be taken with the phenomena of kidney failure, pregnancy and lactation.

In connection with the possibility of cumulation of bismuth, the intake of the drug should not exceed the specified period and be combined with other bismuth-containing drugs.